Company name: Teso Rx Pharma.
Industry: Pharmaceuticals.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Location: Menlo Park, California.
Solution/product: TesoRx Pharma is currently developing TSX-002, an oral testosterone replacement therapy for men with hypogonadism. Its delivery system is intended to provide a convenient, outpatient method of delivering normal physiological levels of testosterone without the side effects associated with abnormally high levels of testosterone and other delivery methods.
Money raised: $5.9 million of a $6.6 million offering, according to a U.S. Securities and Exchange Commission filing. The company raised an undisclosed series A in 2010.
How it will be used: TesoRx held its first pre-IND meeting with the U.S. Food and Drug Administration in March 2011 and recently completed phase 1 trials. It’s now headed for phase 2 trials, according to a company rep.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Investors: Undisclosed.
Management team: CEO/co-founder TR Thirucote was vice president of pharmaceutical sciences at Roxro Pharma, which developed a nasal spray for use in postoperative pain treatment and was acquired by Luitpold Pharmaceuticals in 2010. With co-founder/chief science officer Guru Betageri and co-founder Will Roberts, he runs TesoRx as a virtual company that licenses compounds from small and midsized pharmaceutical companies and commercializes them.
Market size: The estimated prevalence of hypogonadism varies by study, depending on age groups tested and what testosterone level is considered “normal.” TesoRx says about 9 million men in the U.S. are affected by low testosterone — which can cause sexual dysfunction, depression and increased body fat — although only 10 percent of them receive treatment.
Increasing off-label use of testosterone replacement drugs has caused some controversy in recent years and has likely contributed to the rising sales of testosterone replacement therapies, which hit $1.6 million in 2011, according to Bloomberg data.
Competitors: There are no FDA-approved oral therapies on the market, but other testosterone replacement therapies include Solvay Pharmaceuticals’ (Abbott) AndroGel, Eli Lilly’s transdermal Axiron, Auxillium Pharmaceuticals and GlaxoSmithKline’s Testim gel and BioSante’s Bio T-Gel. Repros Therapeutics also has clinical-stage oral drug Androxal.
